The purpose of this study is to find out if the drug ACZ885 (Canakinumab) will improve lung function and also lower inflammation in patients with pulmonary sarcoidosis.
This is a double blind study. This means neither participants nor researchers will know which treatment each participant receives. This is also a placebo controlled study. This means researchers will compare ACZ885 to a placebo in this trial. A placebo looks like a medicine, but does not have an real medicine in it. Using a placebo will help researchers better understand the actual effects of ACZ885. Study participation will last for approximately 6 months and patients receive 6 doses of placebo or ACZ885 once every 4 weeks.
Patients who are selected for this trial will be assigned to one of two treatment groups by a computer:
- ACZ885 group
- Placebo group
Researchers are looking for patients that meet the following characteristics:
- Participants must be between the ages of 18 and 80 years old
- Diagnosed with pulmonary sarcoidosis for more than one year
Criteria that may not allow for you to participate include:
- Diagnosis of pulmonary hypertension requiring treatment
- Women of child-bearing potential who are not using birth control
- View more exclusion criteria
Please reach out to the nearest site listed below for more information on this study and to find out if you may be eligible to participate in the study.The pharmaceutical company, Novartis, sponsors this clinical research study.
- Birmingham, Alabama, USA – University of Alabama at Birmingham
- Albany, New York, USA – Albany Medical Center
Leahruth Saavedra, M.S. 518-262-0355 email@example.com
- Cleveland, Ohio, USA – Cleveland Clinic
Contact: Daniel Culver, D.O. CULVERD@ccf.org
- Essen, Germany
- Hannover, Germany
- Nieuwegein, Netherlands
- Rotterdam, Netherlands
To learn more, view the full trial information on clinicaltrials.gov or contact:
- Novartis Pharmaceuticals
Choosing to participate in a study is an important decision we encourage you to discuss with your physicians, family members, and friends. Every study comes with potential risks and benefits you should discuss thoroughly with you physicians and study coordinators.